SCHEMBL1628971

SCHEMBL1628971

Cc1noc(-c2ccc(C)c(O)c2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 4/20 0.58
ACHE P22303 2/20 0.54
MAPT P10636 2/20 0.49
TP53 P04637 1/20 0.49
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
PDK2 Q15119 1/20 0.46
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
BCHE P06276 1/20 0.45
HTR1A P08908 1/20 0.43
HTR2C P28335 1/20 0.43
MAPK14 Q16539 1/20 0.43
PKM P14618 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092192 0.84 NPC1 (0.63) S1PR1ACHEMAPTTP53NPC1
SCHEMBL1233610 0.81 ACHE (0.56) S1PR1ACHEMAPTTP53NPC1
SCHEMBL27436286 0.79 ACHE (0.64) S1PR1ACHEMAPTTP53NPC1
SCHEMBL10120647 0.79 NPC1 (0.66) S1PR1ACHEMAPTTP53NPC1
SCHEMBL12112410 0.79 ACHE (0.54) S1PR1ACHEMAPTTP53NPC1
SCHEMBL30955218 0.79 ACHE (0.64) S1PR1ACHEMAPTTP53NPC1
SCHEMBL13415305 0.79 ACHE (0.80) ACHEMAPTTP53NPC1RAB9A
SCHEMBL400963 0.78 ACHE (0.67) ACHEMAPTTP53NPC1RAB9A
SCHEMBL18587629 0.78 ESR1 (0.52) S1PR1ACHEMAPTTP53PDK2
SCHEMBL28653849 0.77 S1PR1 (0.63) S1PR1TP53NPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968554-B2 Pyrazolo[3,4-d]pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2011-06-28 US disclosed
US-7968554-B2 Pyrazolo[3,4-d]pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2011-06-28 US disclosed
US-7968554-B2 Pyrazolo[3,4-d]pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2011-06-28 US disclosed
EP-2188290-B1 PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7932390-B2 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives HOFFMAN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932390-B2 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives HOFFMAN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932390-B2 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives HOFFMAN-LA ROCHE INC. (US) 2011-04-26 US disclosed
CN-101965349-A Pyrazolo [3,4-D]-pyrimidine derivatives as antiproliferative HOFFMANN LA ROCHE 2011-02-02 CN disclosed
EP-2038288-B1 NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
EP-2038288-B1 NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
EP-2038288-A1 NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENOÝ3,2¨PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
US-20090048274-A1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES BARTKOVITZ DAVID JOSEPH 2009-02-19 US disclosed
US-20090048274-A1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES BARTKOVITZ DAVID JOSEPH 2009-02-19 US disclosed
US-20090048274-A1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES BARTKOVITZ DAVID JOSEPH 2009-02-19 US disclosed
WO-2009021869-A1 PYRAZOLO[3,4-D]-PYRAMIDINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-19 WO disclosed
US-20080009515-A1 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives CHEN YI 2008-01-10 US disclosed
US-20080009515-A1 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives CHEN YI 2008-01-10 US disclosed
US-20080009515-A1 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives CHEN YI 2008-01-10 US disclosed
WO-2008000697-A1 NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENO[3,2]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed
WO-2008000697-A1 NOVEL 4-AMINO-3-(-AZOLYL-PHENOXYMETHYL)-THIENO[3,2]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048274-A1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES BRAF, RAF1, PRKDC S1PR1 1279/4885ACHE 3935/4885MAPT 2018/4885
US-20080009515-A1 Substituted thieno[3,2-C]pyridine carboxylic acid derivatives UQCRB, UQCRC2, AURKB S1PR1 2684/4885ACHE 4636/4885MAPT 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.